source
- Roche reaffirms sales outlook despite weaker Xolair sales and looming generic competitionRoche reported third-quarter group sales of 16.1 billion Swiss francs, about $19.6 billion, a 7% increase that beat analysts' consensus estimate of 15.8 billion francs. The beat was helped by a ne…
- Regulatory update: Hepatitis B hold lifted for Arbutus drug and Ultomiris receives accelerated approvalA regulatory update notes that the FDA has removed the clinical hold on Arbutus Biopharma's hepatitis B candidate, clearing the path for the company to resume development after a prolonged review.…